As a part of the Hetero Group, our Biologics vertical, comes with a rich legacy – Proven capabilities in the development, manufacturing, and marketing of chemical intermediates, APIs, ARVs, and Finished Dosage Formulations.
With leadership in chemical therapeutics, Hetero continues to lead from the front in the development and manufacturing of Biopharmaceuticals using novel technologies.
Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide. And a majority of our facilities have been successfully audited and approved by stringent regulatory authorities like US FDA, EU, TGA-Australia, MCC-South Africa, and others. Our portfolio includes 300 plus products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology, and Immunology, etc.